Harvest Introduces for International Markets an Autologous Pro-Coagulant for Use With Its SmartPReP(TM) Platelet Gel System

Apr 11, 2001, 01:00 ET from Harvest Technologies Corp.

    PLYMOUTH, Mass., April 11 /PRNewswire/ --Harvest Technologies Corp
 introduces a simple to prepare autologous pro-coagulant positioning Harvest
 with the only platelet gel system made exclusively from the patient's own
 blood. The process requires only 10cc of the patient's blood and is produced
 within the Harvest SmartPReP System at the same time the system separates and
 concentrates the patient's platelets. The platelet concentrate, when mixed
 with the pro-coagulant forms a clot that starts the release of wound healing
 and bone growth proteins contained within the concentrated platelets. A
 totally autologous product is essential for International Markets where
 concern over animal (especially bovine) derived products is acute. Harvest
 recently received its CE on its pro-coagulant system.
     Harvest established Harvest GmbH in Munich in December 2000 to market its
 SmartPReP System and associated disposables. A totally autologous product
 offering will give Harvest GmbH a significant competitive advantage in the
 European Markets.
     Mr. Gary Tureski, Harvest's president states: "Our direct investment in
 the European Market challenged everyone at Harvest to ensure its success. The
 autologous pro-coagulant coupled with our autologous biologic products gives
 Harvest an extremely unique competitive position. A product offering to not
 only Accelerate Healing, Naturally(TM) but also offer an unparalleled level
 safety will position Harvest with a significant competitive advantage in both
 Europe and the Pacific Rim markets."
     Harvest designs innovative products that are intended to Accelerate
 Healing, Naturally(TM).
 
      CONTACT:
      Harvest Technologies Corp
      Kevin Benoit
      General Manager Strategic Business Relations
      Harvest Technologies Corp.
      508-732-7500
      pkbenoit@harvesttech.com
 
 

SOURCE Harvest Technologies Corp.
    PLYMOUTH, Mass., April 11 /PRNewswire/ --Harvest Technologies Corp
 introduces a simple to prepare autologous pro-coagulant positioning Harvest
 with the only platelet gel system made exclusively from the patient's own
 blood. The process requires only 10cc of the patient's blood and is produced
 within the Harvest SmartPReP System at the same time the system separates and
 concentrates the patient's platelets. The platelet concentrate, when mixed
 with the pro-coagulant forms a clot that starts the release of wound healing
 and bone growth proteins contained within the concentrated platelets. A
 totally autologous product is essential for International Markets where
 concern over animal (especially bovine) derived products is acute. Harvest
 recently received its CE on its pro-coagulant system.
     Harvest established Harvest GmbH in Munich in December 2000 to market its
 SmartPReP System and associated disposables. A totally autologous product
 offering will give Harvest GmbH a significant competitive advantage in the
 European Markets.
     Mr. Gary Tureski, Harvest's president states: "Our direct investment in
 the European Market challenged everyone at Harvest to ensure its success. The
 autologous pro-coagulant coupled with our autologous biologic products gives
 Harvest an extremely unique competitive position. A product offering to not
 only Accelerate Healing, Naturally(TM) but also offer an unparalleled level
 safety will position Harvest with a significant competitive advantage in both
 Europe and the Pacific Rim markets."
     Harvest designs innovative products that are intended to Accelerate
 Healing, Naturally(TM).
 
      CONTACT:
      Harvest Technologies Corp
      Kevin Benoit
      General Manager Strategic Business Relations
      Harvest Technologies Corp.
      508-732-7500
      pkbenoit@harvesttech.com
 
 SOURCE  Harvest Technologies Corp.